David R Spriggs

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study
    David R Spriggs
    Division of Solid Tumor Oncology, Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4466-71. 2007
  2. ncbi request reprint Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy
    Mario M Leitao
    Gynecology Service, Department of Surgery, Gynecology Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 91:123-9. 2003
  3. ncbi request reprint Optimal sequencing in the treatment of recurrent ovarian cancer
    David Spriggs
    Departmental Chemotherapy Service, Memorial Sloan Kettering Center and Cornell Weill Medical College, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 90:S39-44. 2003
  4. ncbi request reprint Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas
    Carol Aghajanian
    Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:1082-8. 2007
  5. doi request reprint The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment
    Roisin O'Cearbhaill
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:326-31. 2010
  6. doi request reprint A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    Jason Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 110:140-5. 2008
  7. ncbi request reprint Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer
    Don S Dizon
    Department of Medicine, Division of Developmental Chemotherapy, and Department of Gynecologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 20:1238-47. 2002
  8. pmc Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer
    David M Hyman
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer 118:3703-9. 2012
  9. pmc Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer
    Jason A Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:4662-8. 2011
  10. pmc BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer
    Rachel N Grisham
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 119:548-54. 2013

Detail Information

Publications37

  1. ncbi request reprint Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study
    David R Spriggs
    Division of Solid Tumor Oncology, Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4466-71. 2007
    ..This study was undertaken to assess if prolonged paclitaxel administration in combination with cisplatin improves overall survival (OS) in epithelial ovarian cancer (EOC)...
  2. ncbi request reprint Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy
    Mario M Leitao
    Gynecology Service, Department of Surgery, Gynecology Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 91:123-9. 2003
    ..The objective was to determine the response rate to platinum retreatment of "platinum-resistant" ovarian cancer after intervening nonplatinum therapy...
  3. ncbi request reprint Optimal sequencing in the treatment of recurrent ovarian cancer
    David Spriggs
    Departmental Chemotherapy Service, Memorial Sloan Kettering Center and Cornell Weill Medical College, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 90:S39-44. 2003
    ..The hematologic toxicities associated with topotecan can also be reduced by adjusting the dose and schedule. Prolonged use of topotecan may be feasible and potentially beneficial in some patients...
  4. ncbi request reprint Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas
    Carol Aghajanian
    Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:1082-8. 2007
    ..Dosing schedules of 40 mg/m2 and 50 mg/m2 over 3 hours were also evaluated...
  5. doi request reprint The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment
    Roisin O'Cearbhaill
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:326-31. 2010
    ....
  6. doi request reprint A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    Jason Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 110:140-5. 2008
    ..Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer...
  7. ncbi request reprint Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer
    Don S Dizon
    Department of Medicine, Division of Developmental Chemotherapy, and Department of Gynecologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 20:1238-47. 2002
    ..We sought to determine the outcomes for patients with EOC treated with carboplatin and paclitaxel at the time of first recurrence. In addition, we sought to define a new paradigm for disease transition in patients with EOC...
  8. pmc Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer
    David M Hyman
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer 118:3703-9. 2012
    ..The objective of the current study was to examine whether BRCA1-associated and BRCA2-associated ovarian cancers were associated with different outcomes...
  9. pmc Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer
    Jason A Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:4662-8. 2011
    ..Bevacizumab prolongs progression-free survival (PFS) when included in first-line IV chemotherapy. In this study, the safety and feasibility of adding bevacizumab to a first-line IP regimen were assessed...
  10. pmc BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer
    Rachel N Grisham
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 119:548-54. 2013
    ..In the current study, the authors sought to determine whether BRAF or KRAS mutation status was associated with disease stage and/or histology in patients with SB and LGS ovarian cancer...
  11. pmc Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma
    David M Hyman
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY 10065, USA
    Gynecol Oncol 126:224-8. 2012
    ..BRCA-associated and sporadic ovarian cancers have different pathologic and clinical features. Our goal was to determine if BRCA mutation status is an independent predictor of residual tumor volume following primary surgical cytoreduction...
  12. pmc Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Gynecol Cancer 22:63-9. 2012
    ..We illustrate how the duration of second-line therapy (SLT), the time on the investigational therapy (IT), and patient enrollment plan can affect efficacy measures from maintenance trials and might result in underpowered studies...
  13. ncbi request reprint Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study
    Mika A Sovak
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 103:451-7. 2006
    ..To determine overall survival and progression-free survival among patients with high-risk, stage III and IV endometrial cancer who receive paclitaxel and carboplatin (TC) after complete tumor resection...
  14. pmc Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas
    Xingxing Zang
    Howard Hughes Medical Institute, Immunology Program, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 23:1104-12. 2010
    ..B7-H3 expression in tumor vasculature may be a reflection of tumor aggressiveness and has diagnostic and immunotherapeutic implications in ovarian carcinomas...
  15. ncbi request reprint Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2824-31. 2002
    ..Few chemotherapy agents are active in leiomyosarcoma (LMS), particularly LMS that has progressed after doxorubicin treatment. We sought to determine the response to gemcitabine plus docetaxel among patients with LMS...
  16. doi request reprint Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors
    William P Tew
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:358-66. 2010
    ..To determine the maximum tolerated dose or maximal administered dose and pharmacokinetic and safety profiles of s.c. administered vascular endothelial growth factor Trap (aflibercept), a novel antiangiogenic agent...
  17. pmc The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Cancer Res 18:5179-87. 2012
    ....
  18. doi request reprint Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission
    Catherine S M Diefenbach
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:2740-8. 2008
    ..In this study, we describe the effects of vaccination with the HLA-A*0201-restricted NY-ESO-1b peptide on patients with epithelial ovarian cancer in high-risk first remission...
  19. ncbi request reprint Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer
    Paul J Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:4170-7. 2007
    ....
  20. doi request reprint Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients
    Paul Sabbatini
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 18:6497-508. 2012
    ....
  21. pmc Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma
    Jason Konner
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 30:2294-302. 2012
    ..To determine the maximum tolerated dose and safety of the epothilone, KOS-862, in patients with advanced solid tumors or lymphoma...
  22. doi request reprint Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
    Robert A Soslow
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mod Pathol 25:625-36. 2012
    ..60 (95% CI, 0.32-0.84) and a negative predictive value of 1.0 (95% CI, 0.63-1.0)). These preliminary data indicate potential strong associations between morphology and genotype in high-grade serous carcinomas...
  23. ncbi request reprint Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy
    Don S Dizon
    Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Gynecol Oncol 84:378-82. 2002
    ..One case is presented in which a heavily pretreated patient suffered a severe anaphylactic reaction, which was refractory to standard resuscitative measures and resulted in her death...
  24. pmc Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents
    Thapi D Rao
    Laboratory of Clinical Pharmacology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Mol Cancer Ther 10:1939-48. 2011
    ..The isogenic, dual-color fluorescence strategy is an innovative approach that can effectively identify novel drug candidates, selectively targeting cancer cells that have unique molecular properties...
  25. ncbi request reprint Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors
    Luis H Camacho
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Joan and Sanford I Weill Medical College of Cornell Medical Center, New York, New York, USA
    Invest New Drugs 25:131-8. 2007
    ..However, despite their potential anti-cancer properties, several pharmacodynamic aspects remain unknown...
  26. ncbi request reprint Early detection and prognosis of ovarian cancer using serum YKL-40
    Jakob Dupont
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard 905, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 22:3330-9. 2004
    ..YKL-40 is a secreted glycoprotein (chitinase family). We compared YKL-40 with two ovarian cancer serum markers, CA125 and CA15-3, for the detection of early-stage ovarian cancer...
  27. ncbi request reprint A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
    Carol Aghajanian
    The Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:2505-11. 2002
    ..v. bolus for 2 weeks, followed by a 1-week recovery period in patients with advanced solid tumor malignancies...
  28. ncbi request reprint Non-kinase second-messenger signaling: new pathways with new promise
    Gregory M Springett
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Bioessays 26:730-8. 2004
    ....
  29. pmc Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen
    Alena A Chekmasova
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:3594-606. 2010
    ....
  30. doi request reprint Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16
    Thapi Dharma Rao
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Appl Immunohistochem Mol Morphol 18:462-72. 2010
    ..Development of such antibodies may be useful for the characterization of MUC16 biology and allow for future studies in targeted therapy and diagnostics...
  31. pmc A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Trials 5:465-77. 2008
    ..From a practical perspective, clinicians are interested in designs that can estimate the MTD using fewer patients for a fixed number of doses, or can test more dose levels for a given sample size...
  32. doi request reprint Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study
    William P Tew
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer 120:335-43. 2014
    ....
  33. ncbi request reprint A phase I trial of perillyl alcohol in patients with advanced solid tumors
    Christopher G Azzoli
    Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Chemother Pharmacol 51:493-8. 2003
    ..This phase I trial was conducted to determine the optimal dose of perillyl alcohol...
  34. pmc Genomic complexity and AKT dependence in serous ovarian cancer
    Aphrothiti J Hanrahan
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10471, USA
    Cancer Discov 2:56-67. 2012
    ....
  35. doi request reprint Inclusion of patients with brain metastases in phase I trials: an unmet need
    Mrinal M Gounder
    Developmental Therapeutics Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Cancer Res 17:3855-7. 2011
    ..Tsimberidou and colleagues demonstrate that selected patients can be appropriately enrolled in phase I trials and have outcomes representative of the general cancer population...
  36. ncbi request reprint Consolidation for ovarian cancer in remission
    Paul Sabbatini
    J Clin Oncol 24:537-9. 2006
  37. ncbi request reprint Cancer screening: how good is good enough?
    Martee L Hensley
    J Clin Oncol 22:4037-9. 2004